Physician profile
Sander Binderow
NPI 1023086238
$19,636.92
in general payments reported to CMS, 2019-2025
30 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,978 · 2020: $1,668 · 2021: $4,382 · 2022: $5,351 · 2023: $2,735 · 2024: $1,155 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,893 · Food and Beverage: $1,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,892.65 |
| Food and Beverage | $1,365.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $5,533.09 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Intuitive Surgical, INC. | $4,379.90 | 2019-2022 | |
| Allergan, INC. | $3,558.88 | 2019-2021 | |
| Acell, INC. | $1,117.46 | 2019-2020 | |
| Axonics, INC. | $997.39 | 2020-2021 | |
| Asensus Surgical, INC. | $843.35 | 2019 | |
| Medtronic USA, INC. | $712.49 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $559.19 | 2020-2025 | Gattex |
| Aroa Biosurgery Incorporated | $469.93 | 2022-2024 | |
| Baxter Healthcare | $241.56 | 2021-2025 | Seprafilm |
| Davol INC. | $239.76 | 2019-2025 | Phasix Mesh |
| Medtronic, INC. | $212.78 | 2021-2025 | Interstim, Eea |
| Tetraphase Pharmaceuticals, INC. | $142.03 | 2019 | |
| Abbvie INC. | $126.36 | 2019-2023 | Strattice Reconstructive Tissue Matrix Bps |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.83 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $69.66 | 2025 | Irrisept |
| Braintree Laboratories, INC. | $57.07 | 2022-2024 | Suflave, Sutab |
| La Jolla Pharmaceutical Company | $45.72 | 2021-2023 | Xerava |
| Ethicon US, LLC | $32.96 | 2025 | Echelon Endopath |
| Vertex Pharmaceuticals Incorporated | $27.61 | 2025 | |
| Vioptix INC | $25.60 | 2021 | |
| Merck Sharp & Dohme LLC | $23.21 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $22.22 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.71 | 2019 | |
| Mimedx Group, INC. | $18.70 | 2025 | |
| Palette Life Sciences, INC. | $18.46 | 2022 | |
| Integra Lifesciences Corporation | $16.55 | 2021 | |
| Convatec INC. | $16.12 | 2021 | |
| Solventum Corporation | $14.35 | 2024 | Prevena |
| Prescient Surgical | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sander Binderow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.